Adaptive Biotechnologies Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone, and thanks for joining us for the last session of our health care conference. We're pleased to have Adaptive Biotechnologies with us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, by the way. And with us from Adaptive, we have Chad Robins, CEO of the company.
Questions & Answers
And with that, Chad, maybe as we start here. Adaptive has 2 commercial products, immunoSEQ and clonoSEQ. Can you briefly remind us of the settings in which they're used and the growth levers for both of these on the [ford]?
Sure. Happy to. First, Salveen, thank you for having me. And hopefully, I can do you justice by batting cleanup in the last spot here. In terms of the 2 commercial products, so immunoSEQ is our research product offering that leverages the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |